LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 1 | J19 | 72 | hr | 1476 | 1066 | 3694 | 0.2886 | -0.1852 |
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 2 | J19 | 72 | hr | 1476 | 1182 | 3694 | 0.3200 | -0.1329 |
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 3 | J19 | 72 | hr | 1476 | 1202 | 3694 | 0.3254 | -0.1239 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 1 | M07 | 72 | hr | 1476 | 985 | 3694 | 0.2666 | -0.2218 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 2 | M07 | 72 | hr | 1476 | 1088 | 3694 | 0.2945 | -0.1753 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 3 | M07 | 72 | hr | 1476 | 1186 | 3694 | 0.3211 | -0.1311 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 1 | P13 | 72 | hr | 1476 | 3364 | 3694 | 0.9107 | 0.8512 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 2 | P13 | 72 | hr | 1476 | 3054 | 3694 | 0.8267 | 0.7113 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 3 | P13 | 72 | hr | 1476 | 2983 | 3694 | 0.8075 | 0.6793 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 1 | H01 | 72 | hr | 1476 | 848 | 3694 | 0.2296 | -0.2836 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 2 | H01 | 72 | hr | 1476 | 816 | 3694 | 0.2209 | -0.2980 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 3 | H01 | 72 | hr | 1476 | 906 | 3694 | 0.2453 | -0.2574 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 1 | L19 | 72 | hr | 1476 | 1597 | 3694 | 0.4323 | 0.0542 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 2 | L19 | 72 | hr | 1476 | 1461 | 3694 | 0.3955 | -0.0071 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 3 | L19 | 72 | hr | 1476 | 1599 | 3694 | 0.4329 | 0.0551 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 1 | H07 | 72 | hr | 1476 | 1016 | 3694 | 0.2750 | -0.2078 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 2 | H07 | 72 | hr | 1476 | 1033 | 3694 | 0.2796 | -0.2001 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 3 | H07 | 72 | hr | 1476 | 970 | 3694 | 0.2626 | -0.2285 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 1 | G07 | 72 | hr | 1476 | 1034 | 3694 | 0.2799 | -0.1997 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 2 | G07 | 72 | hr | 1476 | 995 | 3694 | 0.2694 | -0.2173 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 3 | G07 | 72 | hr | 1476 | 979 | 3694 | 0.2650 | -0.2245 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 1 | F01 | 72 | hr | 1476 | 686 | 3694 | 0.1857 | -0.3566 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 2 | F01 | 72 | hr | 1476 | 847 | 3694 | 0.2293 | -0.2840 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 3 | F01 | 72 | hr | 1476 | 1007 | 3694 | 0.2726 | -0.2118 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 1 | G01 | 72 | hr | 1476 | 762 | 3694 | 0.2063 | -0.3223 |